Church of PeptidesSearch
Liraglutide · Chapter 3 of 6

Keep the other column

Human LEADER safety · Published June 13, 2016

What belongs next to a favorable outcome?

Fictional scene

Subject One notices that a display board has a second side. He turns it around and finds the safety table. Doctide pulls up another chair. They leave the jokes outside this room.

What changes here

A favorable primary outcome does not erase adverse events. [1]

Read the study details & dates
Human LEADER safety · Published June 13, 2016

Keep the other column

Same NCT01179048 population and comparison: injected liraglutide versus placebo in high-risk type 2 diabetes. Serious events: 49.7% versus 50.4%; pancreatic cancers: 13 versus 5 (p=0.06). Gallstone disease: 145 versus 90. [1]

What this does not establish

Cancer numbers do not establish causation; the pancreatic-cancer difference was not statistically significant. Event adjudication is not treatment attribution. Individual causal assessments were not verified.

Original sources
  1. Marso et al., NEJM, June 13, 2016 — LEADER primary report

Reviewed November 10, 2026. Primary report safety table; no event-specific causal conclusion asserted.

Up next
What changes when half the participants do not finish?

Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story